American Medical Association News
Most Popular American Medical Association Story
New study highlights risks of anti-TNF antibody class
A new study in the Journal of the American Medical Association concludes that people taking Abbott Laboratories' Humira or Johnson & Johnson's Remicade--both blockbuster meds--face triple the risk of cancer and double the risk of infections. While the chances of getting either cancer or an infection are still small, the study's authors conclude, these anti-TNF antibody drugs still pose threats that people should consider carefully. The drug makers responded by saying that the …
... Read more...Latest Headlines
- August 8, 2006
- July 10, 2006
- July 4, 2006
- June 14, 2006
- January 17, 2006
- December 6, 2005
- September 20, 2005
- July 21, 2005
- July 20, 2005
- June 21, 2005
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


